Investor Presentaiton

To Recap: We are structuring our businesses for long-term sustainable growth and see strong growth opportunities across our key markets • · • 1 'One-India' Bringing together the might of 3 businesses Leveraging strengths across India prescription, Trade generics and Consumer health businesses Strong synergies across portfolio, distribution and consumer focused initiatives US Generics and Specialty 3 Focused and moderated investments across Gx R&D and Specialty built-up Gx R&D investments to be focused towards select value accretive assets • Specialty: Focused investments towards Institutional business; CNS assets to be out-licensed • • 2 Cipla South Africa and Emerging Markets Private market execution in SA; consolidated presence in EMs Strong private market franchise in South Africa; continue to strengthen market leadership in the OTC space as tender business normalizes across the region EM: Focused execution in fewer, bigger markets 4 Lung Leadership across markets Leveraging Cipla's drug-device capabilities to establish a global franchise Establish Cipla as leaders in Lung delivery across key markets (including US and EU) Global co-development and exclusive marketing rights for anti-fungal Inhaled Itraconazole (Pulmazole) Investor Presentation: Q3FY20 13

View entire presentation